TriSalus Life Sciences, Inc. filed its S-4 on Jan 06, 2023 for the period ending Dec 31, 2021. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.4 USD | +0.75% |
|
-0.92% | -36.09% |
06-03 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
05-30 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.09% | 158M | |
+20.17% | 126B | |
+24.67% | 118B | |
+25.12% | 27.87B | |
-17.74% | 20.95B | |
-15.36% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- TLSI Stock
- News TriSalus Life Sciences, Inc.
- TriSalus Life Sciences, Inc. Auditor Raises 'Going Concern' Doubt